Cargando…
Comparison of safety, effectiveness and serum inflammatory factor indexes of Saccharomyces boulardii versus Bifidobacterium triple viable in treating children with chronic diarrhea: a randomized trial
BACKGROUND: Diarrhea is common in children under 5 years of age and is an important public health problem in China. CD is the main obstacle to the growth and development of children, which brings a great burden to individuals, families and society. The objective of this work is to study the efficacy...
Autores principales: | Zhang, Jiawei, Wan, Su, Gui, Qingqing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8261597/ https://www.ncbi.nlm.nih.gov/pubmed/34295782 http://dx.doi.org/10.21037/tp-21-195 |
Ejemplares similares
-
Therapeutic effect of Saccharomyces boulardii combined with Bifidobacterium and on cellular immune function in children with acute diarrhea
por: Wang, Guangmeng, et al.
Publicado: (2019) -
Saccharomyces boulardii to Prevent Antibiotic-Associated Diarrhea: A Randomized, Double-Masked, Placebo-Controlled Trial
por: Ehrhardt, Stephan, et al.
Publicado: (2016) -
Experience with Saccharomyces boulardii Probiotic in Oncohaematological Patients
por: Sulik-Tyszka, Beata, et al.
Publicado: (2017) -
Biocontainment strategies for in vivo applications of Saccharomyces boulardii
por: Hedin, Karl Alex, et al.
Publicado: (2023) -
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Saccharomyces boulardii in Infants and Children With Acute Diarrhea
por: Mourey, Florian, et al.
Publicado: (2020)